[Lipodystrophy: a complication of protease inhibitors in HIV seropositive patients].

Abstract

Indinavir-induced lipodystrophy constitutes a new complication of this therapeutic category. It is characterized by loss of fat from the face and limbs and accumulation of fat in the abdominal wall (possibly simulating an abdominal mass), but also in the abdominal cavity (retroperitoneum, greater omentum, mesocolon, mesentery). This complication, whose frequency is currently assessed to be between 24 to 64%, occurs an average of 10 months after starting treatment. It is often accompanied by laboratory abnormalities, such as hypertriglyceridaemia, hypercholesterolaemia or insulin resistance. The pathophysiology and long-term consequences of this complication are still poorly understood.

• Authors: J F Hermieu, C Leport, V Ravery, V Delmas, L Boccon-Gibod
• Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie (Prog Urol) Vol. 9 Issue 3 Pg. 537-40 (Jun 1999) ISSN: 1166-7087 [Print] France
• Vernacular Title: Lipodystrophies: une complication des inhibiteurs des protéases chez le patient séropositif pour le VIH.
• PMID: 10434332 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Anti-HIV Agents
• HIV Protease Inhibitors

Topics

• Anti-HIV Agents (therapeutic use)
• Drug Therapy, Combination
• HIV Protease Inhibitors (adverse effects)
• HIV Seropositivity (drug therapy)
• Humans
• Lipodystrophy (chemically induced, diagnosis, physiopathology)
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Time Factors